TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: HAART Adherence Interventions in Africa: An RCT
Brief Summary: This study proposes a 4-armed factorial randomized clinical trial in Nairobi, Kenya to determine the effect of cognitive and behavioral interventions on HAART adherence.


Options:
A: Arm Label: Adherence counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adherence counseling | Arm Label: Alarm device; Type: ACTIVE_COMPARATOR; Interventions: Device: Alarm device | Arm Label: Counseling and alarm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adherence counseling, Device: Alarm device | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adherence counseling; Assigned to Arm(s): Adherence counseling, Counseling and alarm | Intervention Type: DEVICE; Name: Alarm device; Assigned to Arm(s): Alarm device, Counseling and alarm
B: Intervention Type: BEHAVIORAL; Name: Semi-structured, open ended interview; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Cell Phone Intervention | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Cell Phone Intervention; Assigned to Arm(s): 1
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mailed education | Arm Label: B; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone coaching program for patients | Arm Label: C; Type: EXPERIMENTAL; Interventions: Behavioral: Telephone coaching program for patients, Behavioral: Medication adherence alert program for doctors | Intervention Type: BEHAVIORAL; Name: Mailed education; Assigned to Arm(s): A | Intervention Type: BEHAVIORAL; Name: Telephone coaching program for patients; Assigned to Arm(s): B, C | Intervention Type: BEHAVIORAL; Name: Medication adherence alert program for doctors; Assigned to Arm(s): C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Inhaled Tiotropium Bromide on Severity of Airflow Obstruction During Long-term Treatment in Patients With Moderately Severe Copd. Impact on Severity and Incidence of Exacerbations.
Brief Summary: The objectives of this study were to evaluate the effect of a one-year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function, incidence and severity of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

The secondary purpose was to explore possible relationships between lung function changes and occurrence of COPD exacerbations and to try to characterize these exacerbations.


Options:
A: Intervention Type: DEVICE; Name: Pulmonary function Testing; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tiotropium bromide; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: tiotropium (Spiriva); Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
D: Arm Label: tiotropium 2.5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 1.25 mcg (2 actuations/day) | Arm Label: tiotropium 18 mcg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium 18 mcg | Arm Label: tiotropium 5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg (2 actuations/day) | Intervention Type: DRUG; Name: tiotropium 18 mcg; Assigned to Arm(s): tiotropium 18 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 1.25 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 2.5 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 5 mcg and placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Inhaled Tiotropium Bromide on Severity of Airflow Obstruction During Long-term Treatment in Patients With Moderately Severe Copd. Impact on Severity and Incidence of Exacerbations.
Brief Summary: The objectives of this study were to evaluate the effect of a one-year treatment with inhaled tiotropium bromide 18 mcg once daily on lung function, incidence and severity of exacerbations in patients with chronic obstructive pulmonary disease (COPD).

The secondary purpose was to explore possible relationships between lung function changes and occurrence of COPD exacerbations and to try to characterize these exacerbations.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium, Drug: Placebo | Arm Label: Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium | Arm Label: Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Placebo | Arm Label: Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol, Drug: Tiotropium, Drug: Placebo | Intervention Type: DRUG; Name: Indacaterol; Assigned to Arm(s): Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg, Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium, Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo, Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg, Sequence 2: Indacaterol 300 μg, Indacaterol 150 μg, Tiotropium, Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Sequence 1: Placebo,Tiotropium, Indacaterol 150 μg, Sequence 3: Indacaterol 150 μg, Indacaterol 300 μg, Placebo, Sequence 4: Tiotropium, Placebo, Indacaterol 300 μg
C: Arm Label: Tiotropium + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium bromide, Drug: Placebo Salmeterol | Arm Label: Salmeterol + Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Salmeterol, Drug: Placebo Tiotropium | Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Salmeterol; Assigned to Arm(s): Salmeterol + Placebo | Intervention Type: DRUG; Name: Placebo Salmeterol; Assigned to Arm(s): Tiotropium + Placebo | Intervention Type: DRUG; Name: Placebo Tiotropium; Assigned to Arm(s): Salmeterol + Placebo
D: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a 9-month Treatment of SPIRIVA® on Health Related Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. Validation of a New HRQoL Questionnaire Appropriate to Common Daily Practice. (TIPHON Study)
Brief Summary: The purpose of this study is to investigate the effect of a 9-month treatment of tiotropium (SPIRIVA®) 18 mcg once daily on Health Related Quality of Life and lung function in patients with a Chronic Obstructive Pulmonary Disease.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: tiotropium (Spiriva); Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel Group, 12 Week Study, Comparing the Effect of Once Daily Tiotropium Lactose Capsule With Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD), naïve to Anticholinergic Agents in Addition to Receiving Their Usual COPD Care
Brief Summary: The objective of the study is to determine the effect on lung function when either SPIRIVA once daily or placebo once daily is added to the usual therapy (care) of COPD patients naïve to anticholinergic agents managed in primary care. Previous studies have been in both hospital in and outpatients, with washout of some respiratory medications, this is the first study to be conducted in General Practice, the drug's anticipated environment.

Data from this study, including the adverse event monitoring, and post study findings on physical examination, will be used to extend the safety database. Health Resource Utilisation (HRU) data will be recorded to be use with data from other sources for economic analysis of COPD treatment.


Options:
A: Intervention Type: DRUG; Name: SPIRIVA; Assigned to Arm(s): N/A
B: Arm Label: Glycopyrronium bromide; Type: EXPERIMENTAL; Interventions: Drug: Glycopyrronium bromide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glycopyrronium bromide; Assigned to Arm(s): Glycopyrronium bromide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: FF/GW642444 Inhalation Powder 100/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 50mcg/25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Powder 200/25 mcg QD; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 25mcg QD; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Powder 100/25 mcg QD, FF/GW642444 Inhalation Powder 200/25 mcg QD, FF/GW642444 Inhalation Powder 50mcg/25mcg QD | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 25mcg QD
D: Arm Label: Tiotropium Respimat 5mcg (Tio R5); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Tiotropium Respimat 10mcg (Tio R10); Type: OTHER; Interventions: Drug: Tiotropium Inhalation Solution | Arm Label: Placebo; Type: OTHER; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Tiotropium Inhalation Solution; Assigned to Arm(s): Tiotropium Respimat 10mcg (Tio R10), Tiotropium Respimat 5mcg (Tio R5) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel Group, 12 Week Study, Comparing the Effect of Once Daily Tiotropium Lactose Capsule With Placebo in Patients With Chronic Obstructive Pulmonary Disease (COPD), naïve to Anticholinergic Agents in Addition to Receiving Their Usual COPD Care
Brief Summary: The objective of the study is to determine the effect on lung function when either SPIRIVA once daily or placebo once daily is added to the usual therapy (care) of COPD patients naïve to anticholinergic agents managed in primary care. Previous studies have been in both hospital in and outpatients, with washout of some respiratory medications, this is the first study to be conducted in General Practice, the drug's anticipated environment.

Data from this study, including the adverse event monitoring, and post study findings on physical examination, will be used to extend the safety database. Health Resource Utilisation (HRU) data will be recorded to be use with data from other sources for economic analysis of COPD treatment.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A
B: Intervention Type: DEVICE; Name: 5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: 10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: SPIRIVA; Assigned to Arm(s): N/A
D: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine
Brief Summary: Malaria in pregnancy is one of the most important preventable causes of low birthweight worlwide and a major cause of severe maternal anaemia contributing to maternal mortality. Intermittent Preventive Treatment (IPT) with sulfadoxine-pyrimethamine (SP) is the currently adopted government recommendation for malaria control during pregnancy in Benin, but the emergence and the spread of resistance to SP justifies the evaluation of alternative anti-malarial drugs. Mefloquine (MQ), which has been proven effective and reasonably safe in this indication, may be an interesting alternative to SP. The aim of this trial is to compare the efficacy and safety of sulfadoxine-pyrimethamine and mefloquine for IPT. It is an equivalent study designed to test the hypothesis that MQ is as efficacious as SP to prevent malaria in pregnancy, and that it could replace SP when resistance of Plasmodium falciparum becomes too elevated. Primary endpoint will be the proportion of infants with low birthweight. Secondary endpoints will be the proportion of mothers with placental plasmodial infection, and the proportion of mothers with anaemia at delivery.


Options:
A: Intervention Type: DRUG; Name: Sulfadoxine-pyrimethamine (Fansidar); Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine | Intervention Type: DRUG; Name: Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine; Assigned to Arm(s): 1, 2, 3
C: Intervention Type: DRUG; Name: sulfadoxine-pyrimethamine / mefloquine; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Insecticide-treated mosquito bed net | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intermittent preventive treatment:sulphadoxine-pyrimethamine, Device: Insecticide-treated mosquito bed net | Intervention Type: DRUG; Name: Intermittent preventive treatment:sulphadoxine-pyrimethamine; Assigned to Arm(s): 1, 3 | Intervention Type: DEVICE; Name: Insecticide-treated mosquito bed net; Assigned to Arm(s): 2, 3

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial Evaluating the Effect of a Vasopressin V2 Receptor Antagonist (SR121463B) on Serum Sodium in Patients With Dilutional Hyponatremia
Brief Summary: Primary:

* To assess the efficacy of SR121463B in correcting hyponatremia in patients with dilutional hyponatremia other than SIADH or cirrhosis

Secondary:

* To assess the long-term efficacy of SR121463B in maintaining normonatremia in these patients
* To assess the safety and tolerability of SR121463B


Options:
A: Intervention Type: DRUG; Name: SR121463B; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: satavaptan (SR121463B); Assigned to Arm(s): N/A
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Spironolactone and furosemide | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: Spironolactone and furosemide | Intervention Type: DRUG; Name: Spironolactone and furosemide; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Spironolactone and furosemide; Assigned to Arm(s): A, B
D: Intervention Type: DRUG; Name: tolvaptan; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of the Effects of Tadalafil and Dexamethasone Versus Placebo on Pulmonary Edema Formation and Cerebral Blood Flow Autoregulation in High Altitude Newcomers With a Previous History of High Altitude Pulmonary Edema
Brief Summary: A double-blind placebo controlled study

* To compare the effect of tadalafil and dexamethasone versus placebo on Ppa and pulmonary edema formation in subjects susceptible to HAPE.
* To investigate the effect of dexamethasone on alveolar fluid clearance, as assessed by measurement of the nasal potential difference, and prevention of HAPE.
* To investigate the effect of the tadalafil and dexamethasone versus placebo on the dynamic CBF autoregulation properties and on the development of AMS in HAPE susceptible subjects.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Aminophylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline | Arm Label: Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methazolamide | Arm Label: Aminophylline+Methazolamide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aminophylline+Methazolamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Aminophylline; Assigned to Arm(s): Aminophylline | Intervention Type: DRUG; Name: Methazolamide; Assigned to Arm(s): Methazolamide | Intervention Type: DRUG; Name: Aminophylline+Methazolamide; Assigned to Arm(s): Aminophylline+Methazolamide
B: Intervention Type: DRUG; Name: dexamethasone 8 mg bid; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: tadalafil 10mg bid; Assigned to Arm(s): N/A
C: Arm Label: Telmisartan/nifedipine; Type: EXPERIMENTAL; Interventions: Drug: Telmisartan, Drug: Nifedipine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Telmisartan; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Telmisartan/nifedipine | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: ascent protocol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: ascent protocol | Intervention Type: BEHAVIORAL; Name: ascent protocol; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Proportion of Patients Experiencing an Exacerbation and Proportion of Patients Hospitalized for an Exacerbation Over 6 Months During Treatment With Tiotropium 18 Mcg Capsule Once Daily in Patients With COPD in a Veterans Affairs Setting
Brief Summary: The primary objective of this trial is to determine whether treatment with tiotropium (18 mcg) capsule once daily via the HandiHaler reduces the proportion of patients with COPD experiencing an exacerbation and the proportion of patients hospitalized for an exacerbation during a six month observation period.


Options:
A: Arm Label: tiotropium 2.5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 1.25 mcg (2 actuations/day) | Arm Label: tiotropium 18 mcg and placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium 18 mcg | Arm Label: tiotropium 5 mcg and placebo; Type: EXPERIMENTAL; Interventions: Drug: tiotropium 2.5 mcg (2 actuations/day) | Intervention Type: DRUG; Name: tiotropium 18 mcg; Assigned to Arm(s): tiotropium 18 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 1.25 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 2.5 mcg and placebo | Intervention Type: DRUG; Name: tiotropium 2.5 mcg (2 actuations/day); Assigned to Arm(s): tiotropium 5 mcg and placebo
B: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): N/A
D: Arm Label: Aclidinium 400 μg bid; Type: EXPERIMENTAL; Interventions: Drug: Aclidinium bromide 400 μg bid | Arm Label: Tiotropium 18 μg once-daily; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium 18 μg once-daily | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aclidinium bromide 400 μg bid; Assigned to Arm(s): Aclidinium 400 μg bid | Intervention Type: DRUG; Name: Tiotropium 18 μg once-daily; Assigned to Arm(s): Tiotropium 18 μg once-daily | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute and Long-term Effects of Once Daily Oral Inhalation of Tiotropium 18 Mcg Dry Powder Inhalation Capsules in a Placebo Controlled Parallel Group Design Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) of Different Severity
Brief Summary: The primary objective of this study is to investigate the effect of tiotropium vs. placebo on trough FEV1 and FEV1 2 hours post inhalation after 12 weeks of treatment. For both endpoints changes from baseline will be analysed. Three strata of patients will be included (severe COPD, i.e. \<35% of predicted FEV1, moderate COPD, i.e. 35% - \<50% of predicted FEV1, mild COPD, i.e. 50% - 70% of predicted FEV1, according to American Thoracic Society \[ATS\] criteria). The study is conducted in order to find out for which endpoint tiotropium is different from placebo in which stratum.


Options:
A: Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A
B: Arm Label: Fluticasone Furoate Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: FF Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF Inhalation Powder | Arm Label: Fluticasone Furoate/GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: FF/GW642444 Inhalation Pwdr; Type: EXPERIMENTAL; Interventions: Drug: FF/GW642444 Inhalation Powder | Arm Label: GW642444 Inhalation Powder; Type: EXPERIMENTAL; Interventions: Drug: GW642444 Inhalation Powder | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FF Inhalation Powder; Assigned to Arm(s): FF Inhalation Pwdr, Fluticasone Furoate Inhalation Powder | Intervention Type: DRUG; Name: FF/GW642444 Inhalation Powder; Assigned to Arm(s): FF/GW642444 Inhalation Pwdr, Fluticasone Furoate/GW642444 Inhalation Powder | Intervention Type: DRUG; Name: GW642444 Inhalation Powder; Assigned to Arm(s): GW642444 Inhalation Powder | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Intervention Type: DRUG; Name: Tiotropium bromide; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Tiotropium bromide 18mcg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluticasone propionate/ salmeterol combination 50/500mcg; Assigned to Arm(s): N/A

Answer: C